Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.6.2215

Analysis on Early Detection of Lung Cancer by PET/CT Scan  

Wang, Huo-Qiang (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
Zhao, Long (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
Zhao, Juan (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
Wang, Qiang (Department of Nuclear Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.6, 2015 , pp. 2215-2217 More about this Journal
Abstract
Background: This systemic analysis was conducted to to evaluate the application value of positron emission tomography/computed tomography (PET/CT) in early diagnosis of lung cancer. Methods: Clinical studies evaluating the application value of PET/CT for patients underwent PET/CT imaging. The histological diagnosis served as the standard of truth. Results: Four clinical studies which including 1330 patients with pulmonary spaceoccupying lesions were considered eligible for inclusion. Systemic analysis suggested that, in all 1330 patients, pooled sensitivity was 98.7% (1313.2/1330) and specificity was 58.2%(276.85/476). Conclusion: This systemic analysis suggests that integrated PET/CT imaging provides high sensitivity, and reasonably high specificity, and could be applied for early diagnosis of lung cancer.
Keywords
Early detection; lung cancer; PET/CT;
Citations & Related Records
Times Cited By KSCI : 10  (Citation Analysis)
연도 인용수 순위
1 Balogova S, Huchet V, Kerrou K, et al (2010). Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun, 31, 389-97.
2 Changlai SP, Tsai SC, Chou MC, et al (2001). Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep, 8, 337-9.
3 Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.   DOI   ScienceOn
4 Demura Y, Tsuchida T, Ishizaki T, et al (2003). 18F-FDG accumulation with PET for differentiation between benign and malignant nodules in the thorax. J Nucl Med, 44, 540-8.
5 Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9.   DOI   ScienceOn
6 Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5.   DOI
7 Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.Asian Pac J Cancer Prev, 15, 1767-9   DOI   ScienceOn
8 Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4.   DOI   ScienceOn
9 Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
10 Kaira K, Yamamoto N, Endo M, et al (2014). 18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. Oncol Rep, 31, 209-215.
11 Lee TS, Ahn SH, Moon BS, et al (2009). Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol, 36, 681-686.   DOI
12 Liu FL, Hong QY, Shi HC, et al (2013). Value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in early diagnosis of lung cancer.Zhonghua Yi Xue Za Zhi, 93, 3019-22.
13 Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5.   DOI   ScienceOn
14 Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8.   DOI   ScienceOn
15 Wang ZX, Zhang B, Wu YW, et al (2011). The clinic value of (18)F-FDG PET/CT imaging in differentiation of malignant from benign disease in lung. Zhonghua Yi Xue Za Zhi, 91, 2456-8.
16 Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection ($Yadanzi^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4.   DOI   ScienceOn
17 Minamimoto R, Senda M, Jinnouchi S, et al (2014). Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey. Anticancer Res, 34, 183-9.
18 Shreve PD, Anzai Y, Wahl RL (1999). Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 19, 61-77.   DOI
19 Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4.   DOI   ScienceOn